DMARDs are a medication that suppresses the immune system. People may take them to slow disease progression in autoimmune or inflammatory conditions, such as different types of arthritis. Inflammation ...

In past decades, remission was seldom assessed as an outcome measure... An earlier randomized, placebo-controlled study of stoppage versus continuation of DMARD therapy in patients with longstanding ...

rheumatoid arthritis dmard vs biologic Updated American College of Rheumatology recommendations suggest using first-line DMARDs in combination with biologic agents and nonbiologic DMARDs to achieve ...

Ankylosing spondylitis is a type of arthritis that inflames joints of the spine and leaves your back stiff and painful. If nonsteroidal anti-inflammatory drugs (NSAIDs) aren't enough to relieve your ...

Most people start a disease modifying antirheumatic drug (DMARD), such as methotrexate, soon after RA diagnosis. If you're still adjusting to a DMARD or want to better understand how it slows joint ...

Please provide your email address to receive an email when new articles are posted on . The American College of Rheumatology has released its updated treatment guidelines for rheumatoid arthritis, ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

In recent years, the treatment of rheumatic inflammatory diseases has been revolutionized. With the advent of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), minimal ...

Please provide your email address to receive an email when new articles are posted on . Maximizing the disease-modifying benefits of methotrexate is one of the core principles behind the 2021 American ...

Only slightly more than half of patients with newly diagnosed rheumatoid arthritis initiated therapy within 1 year. Objectives: To determine the rate of timely disease-modifying antirheumatic drug ...

After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...